ProCE Banner Activity

BELLE-2: Fulvestrant ± Buparlisib in HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
The combination of the investigational PI3K inhibitor buparlisib with fulvestrant extended PFS in patients with HR+/HER2- advanced breast cancer who progressed on previous AI therapy.

Released: December 16, 2015

Expiration: December 14, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation